Inflammation, Platelets and Sickle Cell Disease

Launched by UNIVERSITY HOSPITAL, TOULOUSE · Dec 2, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how inflammation and platelets contribute to the symptoms of sickle cell disease (SCD), particularly during painful crises known as vaso-occlusive crises (VOC). SCD is a genetic condition that leads to the formation of misshapen red blood cells, which can block blood flow and cause severe pain and other complications. The researchers want to better understand what happens in the body during these painful episodes to improve treatment options for patients.

To participate in the trial, individuals must be at least 18 years old and have a confirmed diagnosis of sickle cell disease. They also need to be hospitalized for a VOC and able to give written consent for the study. Participants will not be able to take certain medications like aspirin during the trial. If eligible, participants will undergo assessments to help researchers learn more about the role of inflammation and platelets in their condition. This study aims to gather valuable information that could lead to improved care for those living with sickle cell disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with sickle cell disease diagnosis, hospitalized in emergency department and/or internal medicine department
• • Patient older than 18 years
• • Written consent to participate to the study
• • Patient with health insurance
• • Patient able to receive information about the study
• Exclusion Criteria:
• • Age \< 18 years
• • Non consent to participate to the study
• • Women in pregnancy or breastfeeding
• • Treatment with aspirin or non steroidal anti inflammatory drug
• • Protected patient
• • Patient already involved in a study requiring collection of additional biological samples

Trial Officials